A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

NCT03238651 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Termination of the study by the sponsor due to business decision.

Conditions

Lymphoma, Non-Hodgkin
Lymphoma, Follicular, Marginal Zone

Interventions

DRUG: TAK-659

Sponsor

Calithera Biosciences, Inc